Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation

doi:10.3748/wjg.v13.i9.1435

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2335)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

346

HTML

1461

Figures (1-1)

276

Tables (1-3)

252

Sum=2335

Mar 7, 2007 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Mar 7, 2007; 13(9): 1435-1437
Published online Mar 7, 2007. doi: 10.3748/wjg.v13.i9.1435

Beneficial effect of an antibody against interleukin-2 receptor (daclizumab) in an experimental model of hepatocyte xenotransplantation

Dimitrios Papagoras, Apostolos Papalois, Alexandra Tsaroucha, Dimitrios Lytras, John Kyriazanos, Nikoletta Giannakou, Prodromos Laftsidis, Constantine Simopoulos

Dimitrios Papagoras, Apostolos Papalois, Alexandra Tsaroucha, Dimitrios Lytras, John Kyriazanos, Prodromos Laftsidis, Constantine Simopoulos, 2^nd Department of Surgery, Medical School, “Democritus” University of Thrace, Alexandroupolis, Greece

Apostolos Papalois, Experimental-Research Department, Elpen Pharmaceuticals, Athens, Greece

Nikoletta Giannakou, Department of Pathology, “Aghia Olga” General Hospital, Athens, Greece

Author contributions: All authors contributed equally to the work.

Correspondence to: Apostolos Papalois, PhD, Experimental-Research Department, Elpen Pharmaceuticals, 60 El. Venizelou st., 153 41 Aghia Paraskevi, Athens, Greece. apo@hol.gr

Telephone: +30-210-6537045 Fax: +30-210-6537045

Received: November 30, 2006
Revised: December 25, 2006
Accepted: January 18, 2007
Published online: March 7, 2007

Abstract

AIM: To investigate the use of Daclizumab (Dmab) as an immunosuppressive agent in an experimental model of hepatocyte xenotransplantation (XenoTx) in rats with fulminant hepatic failure (FHF).

METHODS: Two white male New Zealand rabbits were used as donors and 68 Wistar rats as recipients. FHF was induced by intravenous application of dimethylnitrosamine (DMNA). The isolated hepatocytes of the rabbits were xenotransplanted into the spleen of the rats 24 h after FHF induction. Group A (n = 13): no treatment; Group B (n = 14): FHF and XenoTx; Group C (n = 14): FHF and XenoTx and cyclosporin (CsA); Group D (n = 14): FHF and XenoTx and Dmab; Group E (n = 13): FHF and XenoTx and CsA and Dmab. The rats were followed for 15 d.

RESULTS: Statistical analysis showed better survival among groups D (92.86%) and E (76.92%) compared to group A (all rats died after 72 h), group B (28.57%) or group C (71.43%), although the differences were not statistically significant. Biochemical evaluation of the liver enzymes and histology confirmed satisfactory function and engraftment, respectively.

CONCLUSION: This experimental model has shown the safe, effective and beneficial use of Dmab in a xenotransplantation model of rabbit hepatocytes in rats.

Keywords: Transplantation; Hepatocytes; Daclizumab; Cyclosporin